Bioroundup: Stem-cell science and money, genetic tests go political, clinical-trial data woes, and more
(NOTE: Apologies — especially to RSS readers — if you’ve seen this post before, but an apparent server error ate it late yesterday and I was only able to recover it this morning. Enjoy, or ignore, as seems most fit.)
Featured stories:
Stem-cell science, money and death
Gene tests: Out of control?
Clinical-trial data wants to be free
Drug, biotech industries face uncertainty
Short takes
Clones, regrown hearts, money and death — Last week, the San Diego biotech http://www.stemagen.com/… Continue Reading
LIfe sciences briefing: Tuesday, Jan. 15, 2007
TODAY’S HEADLINES:
Pervasis Thera pulls in $9.8M for regenerative medicine (release)
Embrella Cardio receives $2.3M for stroke-prevention heart-surgery devices (release)
Vivendy Thera raises CHF 17M for rare-disease drug (Private Equity Europe)
Novacta Bio gets £3.5M grant for anti-infective drugs (release)
Metavante acquires health-plan admin software co. Bensoft (release)
Pharma-marketing analyst ImpactRx acquires Paragon Research (release)
Arteriocyte gets $509K grant for stem-cell work (release)
HBM BioVentures shoots for Swiss IPO (Reuters)
Covington Capital assumes control of NGB biotech fund (release)
Pervasis Thera pulls in $9.8M for… Continue Reading
Life sciences briefing: Friday, Nov. 30, 2007
Featured companies: Fate Therapeutics, Medgenics, Satoris
UPDATED: Expanded items on Fate Therapeutics and Medgenics. The Satoris item is now a standalone post here.
Fate Therapeutics launches regenerative-medicine quest with $12M — In one of the splashiest launches in recent memory, Seattle’s Fate Therapeutics launched a new regenerative-medicine quest and raised $12 million to help it along. The company aims to develop drugs that redirect fundamental cell biology in ways that mimic the regenerative powers of stem cells, either by… Continue Reading
Is Big Pharma tiptoeing into embryonic stem cells?
(Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.)
For what appears to be the first time, a major drug company has plunked down a significant equity investment in embryonic stem cells.
Earlier today, VentureWire reported (sub required) that Novocell, an early-stage San Diego biotech that aims to treat diabetes with the embryonic cells,… Continue Reading
Is Big Pharma tiptoeing into embryonic stem cells?
For what appears to be the first time, a major drug company has plunked down a significant equity investment in embryonic stem cells.
Earlier today, VentureWire reported (sub required) that Novocell, an early-stage San Diego biotech that aims to treat diabetes with the embryonic cells, is hoping to raise $35 million in a third round of funding. The interesting thing, however, isn’t so much the money as the identity of the lead investor: Johnson & Johnson… Continue Reading